The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s, and research from the 1990s started to reveal its potential as a therapeutic tool.
mRNA became a household name in 2020 and 2021 as arguably the most important global breakthrough of recent years, with its ability to create a specific proteins underpinning vaccine development in response to Covid-19.
EuropaBio is delighted to host the final event of its 25th Anniversary programme with a focus on the story of mRNA. Its first steps into commercial development, challenges to bring a vaccine to millions of people and life beyond Covid – the destination for mRNA in oncology and other significant health applications.
We bring together protagonists from across the spectrum, including:
• Ingmar Hoerr, CureVac Founder and holder of the first patents associated with mRNA
• Stephen Lockhart, Head of EU/AP Vaccines Clinical R&D at Pfizer
• Dhaval Patel, Senior Manager, Manufacturing & Technology, Catalent Biologic